Modulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy

被引：0
|
作者：
Kapp, K. [1 ]
Volz, B. [1 ]
Oswald, D. [1 ]
Wittig, B. [2 ]
Schmidt, M. [1 ]
机构：
[1] Mologen AG, Translat Res, Berlin, Germany
[2] Free Univ Berlin, Fdn Inst Mol Biol & Bioinformat, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
    Capacio, Benedict
    Narayanan, Jayanth Shankara
    Vicente, Diego
    Liu, Yujia
    LaPorte, Jason
    Cox, Bryan
    Jaroch, David
    Katz, Steven
    White, Rebekah Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 729 - 729
  • [42] Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.
    Reilley, Matthew
    Tsimberidou, Apostolia Maria
    Piha-Paul, Sarina Anne
    Yap, Timothy A.
    Fu, Siqing
    Naing, Aung
    Rodon, Jordi
    Ly Minh Nguyen
    Ager, Casey
    Meng, Martin
    Jayaprakash, Priyamvada
    Schmidt, Manuel
    Baumann, Matthias
    Meric-Bernstam, Funda
    Curran, Michael A.
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
    Devaud, Christel
    John, Liza B.
    Westwood, Jennifer A.
    Darcy, Phillip K.
    Kershaw, Michael H.
    ONCOIMMUNOLOGY, 2013, 2 (08):
  • [44] Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
    Carbone, Carmine
    Piro, Geny
    Agostini, Antonio
    Delfino, Pietro
    De Sanctis, Francesco
    Nasca, Vincenzo
    Spallotta, Francesco
    Sette, Claudio
    Martini, Maurizio
    Ugel, Stefano
    Corbo, Vincenzo
    Cappello, Paola
    Bria, Emilio
    Scarpa, Aldo
    Tortora, Giampaolo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [45] Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes
    Meseure, Didier
    Vacher, Sophie
    Alsibai, Kinan Drak
    Trassard, Martine
    Nicolas, Andre
    Leclere, Renaud
    Lerebours, Florence
    Guinebretiere, Jean Marc
    Marangoni, Elisabetta
    Lidereau, Rosette
    Bieche, Ivan
    CANCER MICROENVIRONMENT, 2016, 9 (2-3) : 107 - 118
  • [46] Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano-Immunoadjuvant
    Wei, Jingjing
    Wu, Di
    Zhao, Songsong
    Shao, Yu
    Xia, Yifeng
    Ni, Dawei
    Qiu, Xinyun
    Zhang, Jinping
    Chen, Jian
    Meng, Fenghua
    Zhong, Zhiyuan
    ADVANCED SCIENCE, 2022, 9 (13)
  • [47] Development of the anti-IL-10 mAb MK-1966 in combination with in situ vaccination of a TLR9 agonist SD-101 for cancer immunotherapy
    Phan, U.
    Ueda, R.
    Mangadu, R.
    Sathe, M.
    Rimmer, E.
    Vives, F.
    Ayanoglu, G.
    Yu, Y.
    Wong, J.
    Sadekova, S.
    McClanahan, T.
    Bhagwat, B.
    Willingham, A.
    Raubertas, R.
    Kastelein, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S91 - S92
  • [48] An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
    Zhang, Huagang
    Liu, Laibin
    Yu, Dong
    Kandimalla, Ekambar R.
    Sun, Hui Bin
    Agrawal, Sudhir
    Guha, Chandan
    PLOS ONE, 2012, 7 (05):
  • [49] Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
    Li, Jiali
    Song, Wenru
    Czerwinski, Debra K.
    Varghese, Bindu
    Uematsu, Satoshi
    Akira, Shizuo
    Krieg, Arthur M.
    Levy, Ronald
    JOURNAL OF IMMUNOLOGY, 2007, 179 (04): : 2493 - 2500
  • [50] Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy
    Lutz, Eric R.
    Kinkead, Heather
    Jaffee, Elizabeth M.
    Zheng, Lei
    ONCOIMMUNOLOGY, 2014, 3 (11): : e962401-1 - e962401-3
12345